Protara Therapeutics (TARA) Enterprise Value (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Enterprise Value data on file, last reported at -$135.8 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 9.19% year-over-year to -$135.8 million in Q1 2026; TTM through Mar 2026 was -$135.8 million, a 9.19% decrease from a year earlier, with the FY2025 full-year figure at -$155.6 million, up 8.65% from the prior year.
• Enterprise Value for Q1 2026 stood at -$135.8 million, up from -$155.6 million in the prior quarter.
• Over the last five years, Enterprise Value for TARA reached as high as -$55.2 million in Q1 2024 and fell as low as -$170.3 million in Q4 2024.
• Historically, Enterprise Value has averaged -$106.5 million across 5 years, with a median of -$96.3 million in 2022.
• Across the five-year window, Enterprise Value jumped 57.67% in 2023 and plunged 159.67% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$154.9 million in 2022, then soared by 57.67% to -$65.6 million in 2023, then plunged by 159.67% to -$170.3 million in 2024, then climbed by 8.65% to -$155.6 million in 2025, then advanced by 12.71% to -$135.8 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$135.8 million in Q1 2026, -$155.6 million in Q4 2025, and -$132.7 million in Q3 2025.